Atrium Therapeutics, Inc. (RNA) income statement
RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.64+0.16 (+2.47%)
Close on Nov 18, 2026Market cap $113.58MP/E –Yield –
Atrium Therapeutics, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 10.46
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 180.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.55
- Dividend yield
- –
See a number that looks wrong?